Thomas B. Kepler

Thomas B. Kepler

Auto-generated profile, based on publicly available information

Thomas B. Kepler

Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2013 in Nature
Verified
Journal Article
Open access
PDF file
LHLiao Huaxin
Liao Huaxin
RLRebecca Lynch
Rebecca Lynch
TZTongqing Zhou
Tongqing Zhou
FGFeng Gao
Feng Gao
SAS. Munir Alam
S. Munir Alam
BHBarton F. Haynes
Barton F. Haynes
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gp120 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.

1 December 2001 in Biophysical Journal
Verified
Journal Article
Closed access
TKThomas B. Kepler
Thomas B. Kepler
TETimothy C. Elston
Timothy C. Elston

5 March 2004 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
ELEric Samuel Loker
Eric Samuel Loker
CACoen M. Adema
Coen M. Adema
SZSi‐Ming Zhang
Si‐Ming Zhang
TKThomas B. Kepler
Thomas B. Kepler

7 May 2012 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
BHBarton F Haynes
Barton F Haynes
GKGarnett Kelsoe
Garnett Kelsoe
SHStephen C Harrison
Stephen C Harrison
TKThomas B Kepler
Thomas B Kepler
Failure of immunization with the HIV-1 envelope to induce broadly neutralizing antibodies against conserved epitopes is a major barrier to producing a preventive HIV-1 vaccine. Broadly neutralizing monoclonal antibodies (BnAbs) from those subjects who do produce them after years of chronic HIV-1 infection have one or more unusual characteristics, including polyreactivity for host antigens, extensive somatic hypermutation and long, variable heavy-chain third complementarity-determining regions, factors that may limit their expression by host immunoregulatory mechanisms. The isolation of BnAbs from HIV-1–infected subjects and the use of computationally derived clonal lineages as templates provide a new path for HIV-1 vaccine immunogen design. This approach, which should be applicable to many infectious agents, holds promise for the construction of vaccines that can drive B cells along rare but desirable maturation pathways.

8 August 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JWJames R. R. Whittle
James R. R. Whittle
RZRuijun Zhang
Ruijun Zhang
SKSurender Khurana
Surender Khurana
LKLisa R. King
Lisa R. King
JMJody Manischewitz
Jody Manischewitz
SHStephen C. Harrison
Stephen C. Harrison
Seasonal antigenic drift of circulating influenza virus leads to a requirement for frequent changes in vaccine composition, because exposure or vaccination elicits human antibodies with limited cross-neutralization of drifted strains. We describe a human monoclonal antibody, CH65, obtained by isolating rearranged heavy- and light-chain genes from sorted single plasma cells, coming from a subject immunized with the 2007 trivalent influenza vaccine. The crystal structure of a complex of the hemagglutinin (HA) from H1N1 strain A/Solomon Islands/3/2006 with the Fab of CH65 shows that the tip of the CH65 heavy-chain complementarity determining region 3 (CDR3) inserts into the receptor binding pocket on HA1, mimicking in many respects the interaction of the physiological receptor, sialic acid. CH65 neutralizes infectivity of 30 out of 36 H1N1 strains tested. The resistant strains have a single-residue insertion near the rim of the sialic-acid pocket. We conclude that broad neutralization of influenza virus can be achieved by antibodies with contacts that mimic those of the receptor.

1 October 2011 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
MBMattia Bonsignori
Mattia Bonsignori
KHKwan-Ki Hwang
Kwan-Ki Hwang
XCXi Chen
Xi Chen
CTChun-Yen Tsao
Chun-Yen Tsao
LMLynn Morris
Lynn Morris
BHBarton F. Haynes
Barton F. Haynes
V2/V3 conformational epitope antibodies that broadly neutralize HIV-1 (PG9 and PG16) have been recently described. Since an elicitation of previously known broadly neutralizing antibodies has proven elusive, the induction of antibodies with such specificity is an important goal for HIV-1 vaccine development. A critical question is which immunogens and vaccine formulations might be used to trigger and drive the development of memory B cell precursors with V2/V3 conformational epitope specificity. In this paper we identified a clonal lineage of four V2/V3 conformational epitope broadly neutralizing antibodies (CH01 to CH04) from an African HIV-1-infected broad neutralizer and inferred their common reverted unmutated ancestor (RUA) antibodies. While conformational epitope antibodies rarely bind recombinant Env monomers, a screen of 32 recombinant envelopes for binding to the CH01 to CH04 antibodies showed monoclonal antibody (MAb) binding to the E.A244 gp120 Env and to chronic Env AE.CM243; MAbs CH01 and CH02 also bound to transmitted/founder Env B.9021. CH01 to CH04 neutralized 38% to 49% of a panel of 91 HIV-1 tier 2 pseudoviruses, while the RUAs neutralized only 16% of HIV-1 isolates. Although the reverted unmutated ancestors showed restricted neutralizing activity, they retained the ability to bind to the E.A244 gp120 HIV-1 envelope with an affinity predicted to trigger B cell development. Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies.